CPH Stock Overview
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific.
Notes are coming soon
Creso Pharma Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.02|
|52 Week High||AU$0.099|
|52 Week Low||AU$0.018|
|1 Month Change||0%|
|3 Month Change||-31.03%|
|1 Year Change||-76.47%|
|3 Year Change||-86.67%|
|5 Year Change||-97.81%|
|Change since IPO||-92.31%|
Recent News & Updates
|CPH||AU Pharmaceuticals||AU Market|
Return vs Industry: CPH underperformed the Australian Pharmaceuticals industry which returned -30.2% over the past year.
Return vs Market: CPH underperformed the Australian Market which returned 2.4% over the past year.
|CPH Average Weekly Movement||14.7%|
|Pharmaceuticals Industry Average Movement||9.6%|
|Market Average Movement||8.5%|
|10% most volatile stocks in AU Market||15.6%|
|10% least volatile stocks in AU Market||3.4%|
Stable Share Price: CPH is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CPH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils.
Creso Pharma Limited Fundamentals Summary
|CPH fundamental statistics|
Is CPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPH income statement (TTM)|
|Cost of Revenue||AU$6.10m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0093|
|Net Profit Margin||-241.13%|
How did CPH perform over the long term?See historical performance and comparison